Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SIPPET: methodology, analysis and generalizability

17 Mar 2017

Abstract excerpt

The development of anti-FVIII neutralizing alloantibodies (inhibitors), occurring in about one-third of previously untreated patients (PUPs) with severe haemophilia A, depends on various genetic and environmental risk factors. Several previous studies have reported on the immunogenicity of FVIII concentrates, and due to differences in study design, study period, inhibitor testing frequency and follow-up duration...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
Share to Hemophilia Treatment and Research
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28306186
DOI: 10.1111/hae.13203

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SIPPET: methodology, analysis and generalizabilityPMID 28306186Read ↗

Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis.Semantic proximity Read ↗

Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.Semantic proximity Read ↗

Biological considerations of plasma-derived and recombinant factor VIII immunogenicitySemantic proximity Read ↗

Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.Semantic proximity Read ↗

Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.Semantic proximity Read ↗

Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet studySemantic proximity Read ↗

Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.Semantic proximity Read ↗

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Semantic proximity Read ↗

Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.Semantic proximity Read ↗

Key insights to understand the immunogenicity of FVIII products.Semantic proximity Read ↗

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.Semantic proximity Read ↗

Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia ASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.